Ponatinib · ICLUSIG
Small molecule
Evidence outlook
Approved: Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (2)
- Iclusig 15 mg (Otsuka): CML resistant or intolerant to prior therapy; relapsed or refractory Ph+ ALL
- Iclusig is indicated as monotherapy in adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation. Iclusig...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03589326 NCT03589326 · Ph+ Acute Lymphoblastic Leukemia Patients were randomised to ponatinib or imatinib with the same chemotherapy backbone and the primary comparison reached statistical significance. The primary endpoint is a deep-remission marker measured at the end of induction rather than long-term survival or relapse, and the trial was open-label, so it does not yet show a lasting clinical benefit. Registry: NCT03589326 | 3 | Number of Participants With Minimal Residual Disease (MRD)-Negative Complete Remission (CR) at The End of Induction Phase (From Cycle 1 through Cycle 3 (approximately 3 months) (Cycle length = 28 days)) 2022-08-12 | Number of Participants With Minimal Residual Disease (MRD)-Negative Complete Remission (CR) at The End of Induction Phase (From Cycle 1 through Cycle 3 (approximately 3 months) (Cycle length = 28 days)): Cohort A: Ponatinib 30 mg 53 Participants | Cohort B: Imatinib 600 mg 13 Participants | Partial signal | link ↗ |
View 2 more trials
PACE NCT01207440 · Chronic Myeloid Leukemia The study was a non-randomized, single-arm, open-label trial of 449 participants, with no placebo or active comparator. Its clinical response endpoints were reported descriptively, but without a randomized comparison it cannot establish how much of the observed response was attributable to ponatinib. Registry: NCT01207440 | 2 | Percentage of CP-CML Participants With Major Cytogenetic Response (MCyR) (Up to 12 months after initiation of study treatment); Percentage of AP-CML Participants With Major Hematologic Response (MaHR) (Up to 6 months after initiation of study treatment); Percentage of BP-CML/Ph+ ALL Participants With MaHR (Up to 6 months after initiation of study treatment) 2018-12-20 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
NCT04722848 NCT04722848 · Ph+ Acute Lymphoblastic Leukemia Registry: NCT04722848 | 3 | Number of patients who are event-free (at 5 months) 2027-09 | In progress: results expected 1 Sept 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (41)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 2 (1)
What this study did
Competitive landscape
This drug's own stage for Acute Lymphoblastic Leukemia: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ponatinib (ICLUSIG): this drug | Approved | Small molecule | BCR-ABL (including T315I) | Partial signal | Featured results are non-efficacy only in this race | |
| Blinatumomab | Approved | Multispecific antibody | CD19 x CD3 | Weak signal | NCT03476239: Percentage of Participants With a Hematological Response of Complete Remission (CR) or Complete Remission With Partial Hematological Recovery (CRh*) During the First 2 Treatment Cycles With Blinatumomab (Within 2 cycles of treatment (12 weeks)): Blinatumomab — Interim Analysis: 45.6 percentage of participants (95% CI 35 to 56.4); Final Analysis: 48.3 percentage of participants (95% CI 39.1 to 57.6) | |
| Methotrexate | Approved | Small molecule | Dihydrofolate reductase (DHFR), Folate Analog Metabolic Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Obecabtagene Autoleucel (Aucatzyl) | Approved | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Revumenib | Approved | Small molecule | Menin | Weak signal | No reviewed efficacy summary in this indication | |
| Ziftomenib | Phase 1/2 | Small molecule | Menin | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(16 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow ICLUSIG (Ponatinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.